Formulary Search Results for: ULIPRISTAL ACETATE
7.2.3 Preparations for uterine fibroids - View Category
Restrictions:
The treatment of moderate to severe symptoms of uterine fibroids in adult women is restricted to the following MHRA advice:
- intermittent treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age who are not eligible for surgery or where surgery has failed
- treatment is to be initiated and supervised by a physician experienced in the diagnosis and treatment of uterine fibroids
Please refer to MHRA information prior to initiation.
7.3.5 Emergency contraception - View Category
Prescribing Notes:
- Ulipristal is licensed for use in women presenting up to 120 hours after unprotected intercourse for whom the insertion of an IUD is not acceptable.
- Please follow the FSRH guidance for appropriate use.
11.4.1 Eye-corticosteroids - View Category
9.5.2.2 Phosphate-binding agents - View Category
7.3.2.2 Parenteral progestogen-only contraceptives - View Category
4.8.1 Control of the epilepsies - View Category
Restrictions:
Restricted to initiation by specialists in epilepsy.
Prescribing Notes:
Use as monotherapy in the treatment of partial-onset seizures, with or without generalisation, in adults with newly diagnosed epilepsy is not recommended for use in NHSScotland by the SMC and is non-Formulary.
13.6.1 Topical preparations for acne - View Category
3.4.3 Allergic emergencies - View Category
Restrictions:
It is restricted to specialist use only on the advice of the Immunology Service.
8.2.4 Other immunomodulating drugs - View Category
Restrictions:
Restricted to specialist use only. Restricted to use under the provision of the ‘Risk Sharing Scheme’ between the Scottish Executive Health Department and the manufacturers (NHS HDL (2002)6).
8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocol for the indications as outlined below.
Metastatic castration resistant prostate cancer (mCRPC):
- Use in adult men in whom chemotherapy is not yet clinically indicated after failure of androgen deprivation therapy according to regional protocol
- Use in adult men who have received only one prior chemotherapy regimen. Click here for regional protocol [NHS network access required]
- With prednisone or prednisolone for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy. Click here for regional protocol [NHS network access required]
Non-metastatic prostate cancer:
- Use of abiraterone acetate plus prednisolone in combination with androgen deprivation therapy for the treatment of high-risk hormone-sensitive non-metastatic prostate cancer (off label indication)
Metastatic prostate cancer:
- Abiraterone acetate plus prednisolone in combination with androgen deprivation therapy for the treatment for newly diagnosed low-risk metastatic hormone-sensitive prostate cancer patients who are not suitable for currently accessible on-label alternatives (off label indication).